To recover your password please fill in your email address
Please fill in below form to create an account with us
OCEANiC: A Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients With Stage IIA-IIIA EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection.
|
Trial Summary: |
To evaluate if chemotherapy can be omitted for patients whose tumours are negative for high risk NGS co-mutations and ctDNAin patients with stage IIA-IIIA EGFR-mutant NSCLC following complete surgical resection. |
|
Supported By: |
Astra Zeneca |
|
Eligibility: |
Adults with stage II to IIIA EGFR mutant Non Small Cell Lung Cancer (NSCLC). |
|
Registration ID: |
ACTRN12623000552684 |
|
Participation: |
Australia |
|
Status: |
Recruiting |
|
Activation Date: |
23rd August 2024 |
|
Chairs: |
A/Prof Tom John and Prof Chee Lee |
|
Contact: |